Imai, K.; Takai, K.; Unome, S.; Miwa, T.; Hanai, T.; Suetsugu, A.; Shimizu, M.
Lenvatinib Exacerbates the Decrease in Skeletal Muscle Mass in Patients with Hepatocellular Carcinoma, Whereas Atezolizumab Plus Bevacizumab Does Not. Cancers 2024, 16, 442.
https://doi.org/10.3390/cancers16020442
AMA Style
Imai K, Takai K, Unome S, Miwa T, Hanai T, Suetsugu A, Shimizu M.
Lenvatinib Exacerbates the Decrease in Skeletal Muscle Mass in Patients with Hepatocellular Carcinoma, Whereas Atezolizumab Plus Bevacizumab Does Not. Cancers. 2024; 16(2):442.
https://doi.org/10.3390/cancers16020442
Chicago/Turabian Style
Imai, Kenji, Koji Takai, Shinji Unome, Takao Miwa, Tatsunori Hanai, Atsushi Suetsugu, and Masahito Shimizu.
2024. "Lenvatinib Exacerbates the Decrease in Skeletal Muscle Mass in Patients with Hepatocellular Carcinoma, Whereas Atezolizumab Plus Bevacizumab Does Not" Cancers 16, no. 2: 442.
https://doi.org/10.3390/cancers16020442
APA Style
Imai, K., Takai, K., Unome, S., Miwa, T., Hanai, T., Suetsugu, A., & Shimizu, M.
(2024). Lenvatinib Exacerbates the Decrease in Skeletal Muscle Mass in Patients with Hepatocellular Carcinoma, Whereas Atezolizumab Plus Bevacizumab Does Not. Cancers, 16(2), 442.
https://doi.org/10.3390/cancers16020442